Senhwa Clinical Data Abstract For Silmitasertib In Patients With Advanced Basal Cell Carcinoma Accepted For 2022 AAD Annual Meeting

Published by
The Street

By PR Newswire TAIPEI and SAN DIEGO, Dec. 16, 2021 /PRNewswire/ — Senhwa Biosciences, Inc. (TPEx: 6492), a drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and novel coronaviruses, announced that an abstract highlighting preliminary clinical data for their lead drug candidate, Silmitasertib (CX-4945), in patients with advanced Basal Cell Carcinoma (BCC), has been accepted for e-poster with an oral presentation at the upcoming 2022 American Academy of Dermatology (AAD) annual meeting in Boston, Massachusetts, held from March 25-29, 2022. Presentatio…

Read More

Leave a Reply